Preventing Stroke When You Have Atrial Fibrillation
Atrial fibrillation (AF) causes a fast and erratic heartbeat. Medicines can be used to control the heart rate but AF can also cause blood clots to form in the heart. A blood clot may travel to the brain and cause a stroke. A medicine to prevent clots forming is usually advised for people with AF to reduce the risk of having a stroke.
Why does atrial fibrillation increase your risk of having a stroke?
The main complication of atrial fibrillation (AF) is an increased risk of having a stroke. AF can interfere with the blood flow in the heart chambers. This sometimes leads to a small blood clot forming in a heart chamber.
A clot can travel in the blood vessels until it becomes stuck in a smaller blood vessel in the brain (or sometimes in another part of the body). Part of the blood supply to the brain may then be cut off, which causes a stroke.
The risk of developing a blood clot and having a stroke varies, depending on several factors. The level of risk can be calculated by your doctor using a set of specific questions. This will help to decide what treatments are required. All people except those at the lowest risk will be offered medication to help prevent clots from forming.
How can the risk of stroke be reduced?
Medicines called anticoagulants can be used to reduce the risk of a blood clot and so reduce the risk of stroke. Anticoagulants work by prolonging the time it takes for blood to form a clot. Some people call anticoagulation 'thinning the blood', although the blood is not actually made any thinner.
Anticoagulants reduce the risk of stroke by nearly two thirds. In other words, these treatments can prevent about 6 out of 10 strokes that would have occurred in people with atrial fibrillation (AF).
Should you take medicine to reduce your risk of stroke?
Your doctor can use a risk assessment to see if you should take medicine to reduce your risk of stroke. The most commonly used risk assessment tool is called the CHADS2-VASc risk score. Points are added for each of the following it they apply to you:
- Congestive heart failure with a recent exacerbation (1 point).
- Hypertension - past or present (1 points).
- Aged 75 years or older (2 points).
- Diabetes (1 point).
- Past history of a Stroke or transient ischaemic attack (2 points).
- Vascular disease - eg, peripheral arterial disease, angina or previous heart attack (1 point).
- Age 65-74 years (1 point).
- Sex category (ie female sex scores 1 point and male scores 0).
The higher the total points score, the higher the risk of stroke. Another risk score called the HAS-BLED score is used to estimate the risk of major bleeding when you are taking a medicine to reduce the risk of stroke if you have atrial fibrillation (AF). This helps to decide whether or not the benefits of taking one of the medicines (see below) outweigh the risks.
Which medicines help to reduce the risk of stroke?
The medicines used to prevent a stroke are called anticoagulants. These help to stop blood clots forming in your blood vessels. By far the most commonly used medicine is warfarin. Aspirin is no longer recommended for stroke prevention in people with atrial fibrillation (AF) because it is not very effective.
There are also new medicines that are as effective as warfarin and may have some advantages. These medicines are dabigatran, apixaban, rivaroxaban and edoxaban. The National Institute for Health and Care Excellence (NICE) has recommended that any of these newer medicines can be used to reduce the risk of stroke in patients with AF.
Warfarin can interact with some foods, alcohol and other medicines. Some of the newer anticoagulants (dabigatran, apixaban and rivaroxaban) have less interaction with foods, alcohol and other medicines.
If you take warfarin you will need regular blood tests (INR tests) to check how quickly your blood clots. Blood tests may be needed quite often at first but should become less often quite quickly. The aim is to get the dose of warfarin just right so your blood does not clot as easily as normal but not so much as to cause bleeding problems. Dabigatran, apixaban and rivaroxaban do not need regular blood tests.
What are the benefits and risks of anticoagulant medicines?
The benefit of taking warfarin or one of the newer medicines recommended by National Institute for Health and Care Excellence (NICE) is to reduce your risk of stroke. The main side-effect of these medicines is an increased risk of serious bleeding.
Taking warfarin has a risk of bleeding and the dose of warfarin needs to be checked regularly. Therefore you will need to have regular blood tests if you are taking warfarin. If severe bleeding does happen, an injection of vitamin K will help to stop the effect of warfarin and so help to stop the bleeding.
The newer medicines (dabigatran, apixaban, rivaroxaban and edoxaban) also increase the risk of bleeding but you will not need to have regular blood tests. Apixaban, rivaroxaban and edoxaban currently have no treatment to stop the effect of these medicines if you do have severe bleeding. Dabigatran can be reversed quickly with idarucizumab (Praxbind). However, edoxapan has a lower risk of serious bleeding than warfarin. Apixaban and rivaroxaban do not stay in your body for as long as warfarin does. This mean thats any problem with bleeding disappears more quickly. Usually in 12-24 hours.
There is a lot more information on treatment options on our dedicated leaflet. Follow the link to stroke prevention treatment options.
An operation can be used to reduce the risk of stroke for people with atrial fibrillation (AF). The operation is called left atrial appendage occlusion and closes a pouch in the heart, called the left atrial appendage.
The National Institute for Health and Care Excellence (NICE) has recommended that left atrial appendage occlusion can be considered as a treatment option to reduce the risk of stroke in people with AF.
Further help & information
PO Box 6219, Shipston-on-Stour, Warwickshire, CV37 1NL
Tel: 01789 451837
PO Box 405, Bromley, Kent, BR2 9WP
Tel: 0208 289 6875
Stroke Association House, 240 City Road, London, EC1V 2PR
Tel: (Helpline) 0303 303 3100, (General) 020 7566 0300
Further reading & references
- 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS; European Society of Cardiology (2016)
- Dabigatran etexilate for the prevention of stroke and systemic embolism in atrial fibrillation; NICE Technology Appraisal Guidance, March 2012
- Rivaroxaban for the prevention of stroke and systemic embolism in people with atrial fibrillation; NICE Technology Appraisal Guidance, May 2012
- Apixaban for preventing stroke and systemic embolism in people with nonvalvular atrial fibrillation; NICE Technology Appraisal Guidance, February 2013
- Edoxaban for preventing stroke and systemic embolism in people with non-valvular atrial fibrillation; NICE Technology Appraisal Guidance, September 2015
- Percutaneous occlusion of the left atrial appendage in non-valvular atrial fibrillation for the prevention of thromboembolism; NICE Interventional Procedure Guideline, June 2010
Disclaimer: This article is for information only and should not be used for the diagnosis or treatment of medical conditions. EMIS has used all reasonable care in compiling the information but makes no warranty as to its accuracy. Consult a doctor or other healthcare professional for diagnosis and treatment of medical conditions. For details see our conditions.
Dr Colin Tidy
Dr Colin Tidy
Dr Hannah Gronow